CDEK
← All drugs Report issue

exendin (9-39)

Peptideexperimental

Clinical trial activity

56 trials · 38 clinical orgs · 0 marketing orgs

Phase 1
21
Phase 2
13
Phase 3
3
Phase 4
5

Earliest trial started Feb 1, 1999 (NCT00468091)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • ex-9
  • exendin 3 (heloderma horridum), 1-de-l-histidine-2-de-l-serine-3-de-l-aspartic acid-4-deglycine-5-de-l-threonine-6-de-l-phenylalanine-7-de-l-threonine-8-de-l-serine-
  • exendin (9-39)
  • exendin (9-39)
  • exendin (9-39)
  • exendin 9-39
  • exendin 9-39
  • exendin-(9-39)
  • exendin(9-39)
  • exendin(9-39) 1200
  • exendin(9-39) 300
  • exendin(9-39) 600
  • exendin(9-39) 900
  • exendin (9-39) amide
  • exendin(9-39)amide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06872060N/AJun 1, 2026University of Copenhagen
NCT06972407Phase 2Dec 1, 2025Mayo Clinic
NCT07224334Phase 1Nov 30, 2025Duke University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT06967558Phase 2Nov 1, 2025Mayo Clinic
NCT04652479Phase 2Jun 21, 2021Eiger BioPharmaceuticals, Stanford University
NCT04459338Phase 3Jan 31, 2021Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT04466566Phase 3Jan 31, 2021Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT04466618Phase 3Dec 31, 2020Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03950245N/AMay 31, 2019University of Copenhagen
NCT03373435Phase 2Mar 19, 2018Eiger BioPharmaceuticals
NCT02971631N/AAug 10, 2017University of Cambridge
NCT03241303N/AAug 1, 2017University of Copenhagen
NCT02844907Phase 4Aug 1, 2017Department of Veteran Affairs, Duke University
NCT03246451N/AJul 1, 2017University of Copenhagen
NCT03101930Phase 4May 1, 2017American Heart Association, Vanderbilt University
NCT02779075N/AJun 1, 2016Mayo Clinic, The Obesity Society
NCT02771574Phase 2May 1, 2016Stanford University
NCT02550548Phase 1Apr 21, 2016Duke University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02762708N/AMar 1, 2016Mayo Clinic
NCT02697253N/AJan 1, 2016Columbia University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Showing 20 of 56 trials
Page 1 / 3

Organizations

Research & Development (38)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government13042007
Mayo ClinicAcademic/Hospital121242011
University of CopenhagenAcademic/Hospital6612013
Ludwig Maximilians UniversityAcademic/Hospital5511999
National Institutes of Health (NIH)Government4032007
Stanford UniversityAcademic/Hospital4422014
University of PennsylvaniaAcademic/Hospital4422007
Cedars-Sinai Medical CenterAcademic/Hospital3312005
Duke UniversityAcademic/Hospital3322016
National Center for Research Resources (NCRR)Government3012011
Columbia UniversityAcademic/Hospital2212014
Department of Veteran AffairsGovernment2112010
Eiger BioPharmaceuticalsFor profit2112018
Free University of AmsterdamAcademic/Hospital2012011
German Research FoundationAcademic/Hospital2011999
MerckFor profit2012006
University of AmsterdamAcademic/Hospital2212011
University of BernAcademic/Hospital2222011
University of CincinnatiAcademic/Hospital2212013
Vanderbilt UniversityAcademic/Hospital2212013
38 organizations
Page 1 / 2